15 results on '"Renzelli V"'
Search Results
2. Diabetes management in cancer patients. An Italian Association of Medical Oncology, Italian Association of Medical Diabetologists, Italian Society of Diabetology, Italian Society of Endocrinology and Italian Society of Pharmacology multidisciplinary consensus position paper
- Author
-
Silvestris, N., Franchina, T., Gallo, M., Argentiero, A., Avogaro, A., Cirino, G., Colao, A., Danesi, R., Di Cianni, G., D’Oronzo, S., Faggiano, A., Fogli, S., Giuffrida, D., Gori, S., Marrano, N., Mazzilli, R., Monami, M., Montagnani, M., Morviducci, L., Natalicchio, A., Ragni, A., Renzelli, V., Russo, A., Sciacca, L., Tuveri, E., Zatelli, M.C., Giorgino, F., and Cinieri, S.
- Published
- 2023
- Full Text
- View/download PDF
3. MiRNA dysregulation underlying common pathways in type 2 diabetes and cancer development: an Italian Association of Medical Oncology (AIOM)/Italian Association of Medical Diabetologists (AMD)/Italian Society of Diabetology (SID)/Italian Society of Endocrinology (SIE)/Italian Society of Pharmacology (SIF) multidisciplinary critical view
- Author
-
Natalicchio, A., Montagnani, M., Gallo, M., Marrano, N., Faggiano, A., Zatelli, M.C., Mazzilli, R., Argentiero, A., Danesi, R., D’Oronzo, S., Fogli, S., Giuffrida, D., Gori, S., Ragni, A., Renzelli, V., Russo, A., Franchina, T., Tuveri, E., Sciacca, L., Monami, M., Cirino, G., Di Cianni, G., Colao, A., Avogaro, A., Cinieri, S., Silvestris, N., and Giorgino, F.
- Published
- 2023
- Full Text
- View/download PDF
4. Cancer related safety with SGLT2-i and GLP1-RAs: should we worry?
- Author
-
Gallo, M., primary, Monami, M., additional, Ragni, A., additional, and Renzelli, V., additional
- Published
- 2023
- Full Text
- View/download PDF
5. Expected and paradoxical effects of obesity on cancer treatment response
- Author
-
Gallo, M, Adinolfi, V, Barucca, V, Prinzi, N, Renzelli, V, Barrea, L, Di Giacinto, P, Ruggeri, Rm, Sesti, F, Arvat, E, Baldelli, R, Eolo, Group, Colao, A, Isidori, A, Lenzi, A, Baldell, R, Albertelli, M, Attala, D, Bianchi, A, Di Sarno, A, Feola, T, Mazziotti, G, Nervo, A, Pozza, C, Puliani, G, Razzore, P, Ramponi, S, Ricciardi, S, Rizza, L, Rota, F, Sbardella, E, and Zatelli, Mc.
- Subjects
Oncology ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,030209 endocrinology & metabolism ,body mass index ,cancer ,cancer therapy ,obesity ,overweight ,treatment outcome ,Overweight ,NO ,Body Mass Index ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Risk Factors ,Internal medicine ,Diabetes mellitus ,Neoplasms ,Epidemiology ,medicine ,Humans ,Cancer ,Obesity ,Body mass index ,Cancer therapy ,Treatment outcome ,LS4_3 ,Risk factor ,business.industry ,medicine.disease ,Prognosis ,Cardiovascular Diseases ,medicine.symptom ,business ,Obesity paradox - Abstract
Obesity, whose prevalence is pandemic and continuing to increase, is a major preventable and modifiable risk factor for diabetes and cardiovascular diseases, as well as for cancer. Furthermore, epidemiological studies have shown that obesity is a negative independent prognostic factor for several oncological outcomes, including overall and cancer-specific survival, for several site-specific cancers as well as for all cancers combined. Yet, a recently growing body of evidence suggests that sometimes overweight and obesity may associate with better outcomes, and that immunotherapy may show improved response among obese patients compared with patients with a normal weight. The so-called 'obesity paradox' has been reported in several advanced cancer as well as in other diseases, albeit the mechanisms behind this unexpected relationship are still not clear. Aim of this review is to explore the expected as well as the paradoxical relationship between obesity and cancer prognosis, with a particular emphasis on the effects of cancer therapies in obese people.
- Published
- 2020
6. Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper
- Author
-
Antongiulio Faggiano, Rossella Mazzilli, Annalisa Natalicchio, Valerio Adinolfi, Antonella Argentiero, Romano Danesi, Stella D’Oronzo, Stefano Fogli, Marco Gallo, Dario Giuffrida, Stefania Gori, Monica Montagnani, Alberto Ragni, Valerio Renzelli, Antonio Russo, Nicola Silvestris, Tindara Franchina, Enzo Tuveri, Saverio Cinieri, Annamaria Colao, Francesco Giorgino, Maria Chiara Zatelli, Faggiano A., Mazzilli R., Natalicchio A., Adinolfi V., Argentiero A., Danesi R., D'Oronzo S., Fogli S., Gallo M., Giuffrida D., Gori S., Montagnani M., Ragni A., Renzelli V., Russo A., Silvestris N., Franchina T., Tuveri E., Cinieri S., Colao A., Giorgino F., and Zatelli M.C.
- Subjects
Consensus ,Survival ,Tumour response ,Settore MED/06 - Oncologia Medica ,Contraindications ,Hematology ,Medical Oncology ,Italy ,Oncology ,Adrenal Cortex Hormones ,Dose ,Adverse events ,Humans ,Corticosteroids ,Indications ,Glucocorticoids ,Societies, Medical ,Cancer - Abstract
Corticosteroids (CSs) are widely used in oncology, presenting several different indications. They are useful for induction of apoptosis in hematological neoplasms, for management of anaphylaxis and cytokine release/hypersensitivity reaction and for the symptomatic treatment of many tumour- and treatment-related complications. If the employment of CSs in the oncological setting results in several benefits for patients and satisfaction for clinicians, on the other hand, many potential adverse events (AEs), both during treatment and after withdrawal of CSs, as well as the duality of the effects of these compounds in oncology, recommend being cautious in clinical practice. To date, several gray zones remain about indications, contraindications, dose, and duration of treatment. In this article, a panel of experts provides a critical review on CSs therapy in oncology, focusing on mechanisms of action and pharmacological characteristics, current and emerging therapeutic indications/contraindications, AEs related to CSs treatment, and the impact on patient outcome.
- Published
- 2022
7. Cancer related safety with SGLT2-i and GLP1-RAs: should we worry?
- Author
-
Gallo, M., Monami, M., Ragni, A., and Renzelli, V.
- Full Text
- View/download PDF
8. Nutritional status and follicular-derived thyroid cancer: An update
- Author
-
Paola Di Giacinto, Natalie Prinzi, Annamaria Colao, Roberto Baldelli, Valerio Adinolfi, Valerio Renzelli, Viola Barucca, Franz Sesti, Luigi Barrea, Marco Gallo, Rosaria Maddalena Ruggeri, Giovanna Muscogiuri, Barrea, L., Gallo, M., Ruggeri, R. M., Giacinto, P. D., Sesti, F., Prinzi, N., Adinolfi, V., Barucca, V., Renzelli, V., Muscogiuri, G., Colao, A., and Baldelli, R.
- Subjects
dietary factor ,nutritional factors ,030309 nutrition & dietetics ,Physiology ,Nutritional Status ,Industrial and Manufacturing Engineering ,03 medical and health sciences ,0404 agricultural biotechnology ,Adenocarcinoma, Follicular ,medicine ,Animals ,Obesity ,Thyroid Neoplasms ,nutritional factor ,follicular thyroid cancer ,dietary factors ,dietary pattern ,nutritionist ,obesity ,Follicular thyroid cancer ,Thyroid cancer ,0303 health sciences ,Animal ,business.industry ,Thyroid ,Cancer ,04 agricultural and veterinary sciences ,General Medicine ,medicine.disease ,040401 food science ,Iodine deficiency ,Nutritional Statu ,Malnutrition ,medicine.anatomical_structure ,Thyroid function ,business ,Food Science ,Iodine - Abstract
The incidence of differentiated thyroid cancer has been increasing in the last decades all over the world. Such a steady growth cannot be entirely attributable to more intensive thyroid nodule screening and more sensitive diagnostic procedures. Several environmental factors have changed with sufficient rapidity in the same time frame and may represent credible candidates for this increase. They include modified iodine intake, lifestyle-associated risk factors, exposure to various toxic compounds, pollutants and xenobiotics, nutritional deficiencies, eating habits and comorbidities. Foremost, nutritional patterns have gained high interest as possible promoters and modifiable risk factors for thyroid cancer in recent years. The aim of this narrative review is to focus on the relationship between thyroid cancer and nutritional factors, dietary habits and obesity. Low iodine intake has been associated to increased risk of thyroid cancer, favoring the development of more aggressive histotypes. Moreover, correction of iodine deficiency can shift thyroid cancer subtypes toward less aggressive forms, without affecting the overall risk for cancer. Actually, evidence regarding the association between selenium and vitamin D deficiency and thyroid cancer is very limited, despite their well-known anti-cancer potentials, and the clinical usefulness of their supplementation is still uncertain in this setting. Albeit the relationship between single foods and thyroid cancer is difficult to examine, fish and iodine-rich foods, vegetables, and fruits might exert protective effects on thyroid cancer risk. Conversely, no clear association has been found for other foods to date. Lastly, a clear association between obesity and the risk of thyroid cancer, with more aggressive behavior, seems to emerge from most studies, likely involving variations in thyroid function and chronic inflammation mediated by cytokines, insulin, leptin and adiponectins. Although no definite association between dietary factors and thyroid cancer has been firmly established so far, some nutritional patterns, together with excessive weight, seem to play a relevant role in thyroid cancer carcinogenesis as well as in its severity and aggressiveness. These effects may play an additive role to the well-established one exerted by environmental carcinogens, such as pollutants and radiation exposure.
- Published
- 2020
9. Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE) and Italian Society of Pharmacology (SIF) multidisciplinary group.
- Author
-
Zatelli MC, Faggiano A, Argentiero A, Danesi R, D'Oronzo S, Fogli S, Franchina T, Giorgino F, Marrano N, Giuffrida D, Gori S, Marino G, Mazzilli R, Monami M, Montagnani M, Morviducci L, Natalicchio A, Ragni A, Renzelli V, Russo A, Sciacca L, Tuveri E, Aimaretti G, Avogaro A, Candido R, Di Maio M, Silvestris N, and Gallo M
- Subjects
- Humans, Italy, Checklist, Immune Checkpoint Inhibitors therapeutic use, Societies, Medical standards, Endocrine System Diseases chemically induced, Medical Oncology methods, Neoplasms drug therapy, Neoplasms immunology, Neoplasms therapy, Immunotherapy methods
- Abstract
Immunotherapy with immune checkpoint inhibitors (ICI) is increasingly employed in oncology. National and international endocrine and oncologic scientific societies have provided guidelines for the management of endocrine immune-related adverse events. However, guidelines recommendations differ according to the specific filed, particularly pertaining to recommendations for the timing of endocrine testing. In this position paper, a panel of experts of the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), and Italian Society of Pharmacology (SIF) offers a critical multidisciplinary consensus for a clear, simple, useful, and easily applicable endocrine-metabolic assessment checklist for cancer patients on immunotherapy., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: V.R. has received a travel grant from Androlabs. M.G. has received honoraria for speaker fees and/or travel grants for scientific meetings from AAA, AstraZeneca, Boehringer-Ingelheim, Bruno Farm., Eli-Lilly, IBSA, Lifescan, Mundipharma, Novo Nordisk and Sanofi, and served on scientific advisory panels for Boehringer-Ingelheim, Merck Sharp & Dohme and Novo Nordisk. S.F. serves on the scientific advisory board of, has a consulting relationship with and reports receiving support for travel expenses from Novartis, Teva, Roche, BMS, Lilly and Ipsen. R.D. serves on the scientific advisory board and has a consulting relationship with Ipsen, Novartis, Pfizer, Sanofi Genzyme, AstraZeneca, Janssen, Gilead, Lilly, Gilead, EUSA Pharma; and reports support for travel, accommodation and expenses from Ipsen and Sanofi Genzyme. F.G. has served as an advisor for AstraZeneca, Eli Lilly and Novo Nordisk; has served as a research investigator for Eli Lilly and Roche Diabetes Care; has served as a speaker for AstraZeneca and Eli Lilly; has served as a consultant for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, Roche Diabetes Care and Sanofi; and has received grants from Eli Lilly, Lifescan and Roche Diabetes Care. N.S. received fees for consulting from Roche, Lilly, Servier. All other authors declare no conflict of interest. All other authors have declared no conflicts of interest., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
10. Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials.
- Author
-
Silverii GA, Monami M, Gallo M, Ragni A, Prattichizzo F, Renzelli V, Ceriello A, and Mannucci E
- Subjects
- Humans, Hypoglycemic Agents therapeutic use, Glucagon-Like Peptide-1 Receptor Agonists, Randomized Controlled Trials as Topic, Glucagon-Like Peptide-1 Receptor agonists, Diabetes Mellitus, Type 2 drug therapy, Thyroid Neoplasms chemically induced, Thyroid Neoplasms epidemiology
- Abstract
Aim: To conduct a meta-analysis of randomized clinical trials (RCTs) to investigate whether there is an association between glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment and thyroid cancer., Materials and Methods: In this meta-analysis of RCTs, we included studies comparing a GLP-1RA with any comparator, lasting at least 52 weeks, and reporting the incidence of adverse events independently of the principal endpoint and population. All cases of thyroid cancer were collected., Results: We retrieved 64 trials, 26 of which reported at least one incident case of thyroid cancer. GLP-1RA treatment was associated with a significant increase in the risk of overall thyroid cancer (Mantel-Haenzel odds ratio [MH-OR] 1.52 [95% confidence interval {CI} 1.01, 2.29]; P = 0.04, I
2 = 0%), with a fragility index of 1, and a 5-year number needed to harm of 1349. The association remained significant when including only trials lasting at least 104 weeks (MH-OR 1.76 [95% CI 1.00, 3.12]; P = 0.05). No significant association was found for papillary thyroid cancer (MH-OR 1.54 [95% CI 0.77, 3.06]; P = 0.22) or medullary thyroid cancer (MH-OR 1.44 [95% CI 0.23, 9.16]; P = 0.55)., Conclusions: Our meta-analysis showed that GLP-1RA treatment could be associated with a moderate increase in relative risk for thyroid cancer in clinical trials, with a small increase in absolute risk. Studies of longer duration are required to assess the clinical implications of this finding., (© 2023 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.)- Published
- 2024
- Full Text
- View/download PDF
11. Polybrominated Diphenyl Ethers (PBDEs) and Human Health: Effects on Metabolism, Diabetes and Cancer.
- Author
-
Renzelli V, Gallo M, Morviducci L, Marino G, Ragni A, Tuveri E, Faggiano A, Mazzilli R, Natalicchio A, Zatelli MC, Montagnani M, Fogli S, Giuffrida D, Argentiero A, Danesi R, D'Oronzo S, Gori S, Franchina T, Russo A, Monami M, Sciacca L, Cinieri S, Colao A, Avogaro A, Di Cianni G, Giorgino F, and Silvestris N
- Abstract
There is increasing evidence of the role of endocrine disruptors (EDs) derived from commonly employed compounds for manufacturing and processing in altering hormonal signaling and function. Due to their prolonged half-life and persistence, EDs can usually be found not only in industrial products but also in households and in the environment, creating the premises for long-lasting exposure. Polybrominated diphenyl ethers (PBDEs) are common EDs used in industrial products such as flame retardants, and recent studies are increasingly showing that they may interfere with both metabolic and oncogenic pathways. In this article, a multidisciplinary panel of experts of the Italian Association of Medical Diabetologists (AMD), the Italian Society of Diabetology (SID), the Italian Association of Medical Oncology (AIOM), the Italian Society of Endocrinology (SIE) and the Italian Society of Pharmacology (SIF) provides a review on the potential role of PBDEs in human health and disease, exploring both molecular and clinical aspects and focusing on metabolic and oncogenic pathways.
- Published
- 2023
- Full Text
- View/download PDF
12. Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper.
- Author
-
Faggiano A, Mazzilli R, Natalicchio A, Adinolfi V, Argentiero A, Danesi R, D'Oronzo S, Fogli S, Gallo M, Giuffrida D, Gori S, Montagnani M, Ragni A, Renzelli V, Russo A, Silvestris N, Franchina T, Tuveri E, Cinieri S, Colao A, Giorgino F, and Zatelli MC
- Subjects
- Humans, Consensus, Contraindications, Adrenal Cortex Hormones therapeutic use, Italy, Medical Oncology methods, Societies, Medical
- Abstract
Corticosteroids (CSs) are widely used in oncology, presenting several different indications. They are useful for induction of apoptosis in hematological neoplasms, for management of anaphylaxis and cytokine release/hypersensitivity reaction and for the symptomatic treatment of many tumour- and treatment-related complications. If the employment of CSs in the oncological setting results in several benefits for patients and satisfaction for clinicians, on the other hand, many potential adverse events (AEs), both during treatment and after withdrawal of CSs, as well as the duality of the effects of these compounds in oncology, recommend being cautious in clinical practice. To date, several gray zones remain about indications, contraindications, dose, and duration of treatment. In this article, a panel of experts provides a critical review on CSs therapy in oncology, focusing on mechanisms of action and pharmacological characteristics, current and emerging therapeutic indications/contraindications, AEs related to CSs treatment, and the impact on patient outcome., (Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
13. Cortisol Deficiency in Lenvatinib Treatment of Thyroid Cancer: An Underestimated Common Adverse Event.
- Author
-
Monti S, Presciuttini F, Deiana MG, Motta C, Mori F, Renzelli V, Stigliano A, Toscano V, Pugliese G, and Poggi M
- Subjects
- Adult, Aged, Aged, 80 and over, Drug-Related Side Effects and Adverse Reactions diagnosis, Female, Humans, Hydrocortisone metabolism, Male, Middle Aged, Phenylurea Compounds therapeutic use, Protein Kinase Inhibitors adverse effects, Protein Kinase Inhibitors therapeutic use, Quinolines therapeutic use, Thyroid Neoplasms physiopathology, Drug-Related Side Effects and Adverse Reactions complications, Hydrocortisone deficiency, Phenylurea Compounds adverse effects, Quinolines adverse effects, Thyroid Neoplasms drug therapy
- Abstract
Background: Lenvatinib treatment has shown a significant improvement in progression-free survival in patients with metastatic, progressive, radioiodine-refractory differentiated thyroid cancer, although its use is associated with considerable toxicity. Fatigue is one of the most frequent adverse events (AEs). It has been reported that adrenal insufficiency (AI) may be involved in lenvatinib-related fatigue. In our study, we assessed the pituitary/adrenal axis before and during treatment, and the possible involvement of AI in lenvatinib-related fatigue. This was done to clarify the incidence, development, and time course of AI during lenvatinib treatment. Methods: We studied 13 patients who were selected for lenvatinib therapy. Adrenal function was evaluated by measuring cortisol and adrenocorticotropic hormone (ACTH) levels and through the ACTH (250 μg) stimulation test. Results: During treatment, seven patients (54%) developed AI. High levels of ACTH were observed in accordance with the diagnosis of primary AI (PAI). By evaluating the first ACTH test, before starting lenvatinib treatment, we found that patients with <646.6 nmol/L cortisol peak had an increased risk of developing PAI during lenvatinib treatment. Fatigue was observed in 11 patients (84.6%) during lenvatinib treatment. Cortisone acetate treatment induced an improvement in fatigue in six of seven patients (85.7%) in the PAI group, without the need to change the lenvatinib dosage. Conclusions: PAI may be considered one of the most common AEs associated with lenvatinib. Our data strongly suggest that PAI could be involved in lenvatinib-associated fatigue, particularly in patients with extreme fatigue. In this context, early diagnosis of PAI is essential, especially since glucocorticoid replacement therapy can induce a significant improvement in fatigue, without the need to reduce the dosage of lenvatinib. However, further studies are required to confirm these preliminary findings.
- Published
- 2022
- Full Text
- View/download PDF
14. Expected and paradoxical effects of obesity on cancer treatment response.
- Author
-
Gallo M, Adinolfi V, Barucca V, Prinzi N, Renzelli V, Barrea L, Di Giacinto P, Ruggeri RM, Sesti F, Arvat E, Baldelli R, Arvat E, Colao A, Isidori A, Lenzi A, Baldell R, Albertelli M, Attala D, Bianchi A, Di Sarno A, Feola T, Mazziotti G, Nervo A, Pozza C, Puliani G, Razzore P, Ramponi S, Ricciardi S, Rizza L, Rota F, Sbardella E, and Zatelli MC
- Subjects
- Body Mass Index, Humans, Obesity complications, Obesity epidemiology, Obesity therapy, Overweight, Prognosis, Risk Factors, Cardiovascular Diseases epidemiology, Neoplasms etiology, Neoplasms therapy
- Abstract
Obesity, whose prevalence is pandemic and continuing to increase, is a major preventable and modifiable risk factor for diabetes and cardiovascular diseases, as well as for cancer. Furthermore, epidemiological studies have shown that obesity is a negative independent prognostic factor for several oncological outcomes, including overall and cancer-specific survival, for several site-specific cancers as well as for all cancers combined. Yet, a recently growing body of evidence suggests that sometimes overweight and obesity may associate with better outcomes, and that immunotherapy may show improved response among obese patients compared with patients with a normal weight. The so-called 'obesity paradox' has been reported in several advanced cancer as well as in other diseases, albeit the mechanisms behind this unexpected relationship are still not clear. Aim of this review is to explore the expected as well as the paradoxical relationship between obesity and cancer prognosis, with a particular emphasis on the effects of cancer therapies in obese people., (© 2020. Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2021
- Full Text
- View/download PDF
15. Nutritional status and follicular-derived thyroid cancer: An update.
- Author
-
Barrea L, Gallo M, Ruggeri RM, Giacinto PD, Sesti F, Prinzi N, Adinolfi V, Barucca V, Renzelli V, Muscogiuri G, Colao A, and Baldelli R
- Subjects
- Animals, Nutritional Status, Obesity complications, Adenocarcinoma, Follicular, Iodine, Thyroid Neoplasms etiology
- Abstract
The incidence of differentiated thyroid cancer has been increasing in the last decades all over the world. Such a steady growth cannot be entirely attributable to more intensive thyroid nodule screening and more sensitive diagnostic procedures. Several environmental factors have changed with sufficient rapidity in the same time frame and may represent credible candidates for this increase. They include modified iodine intake, lifestyle-associated risk factors, exposure to various toxic compounds, pollutants and xenobiotics, nutritional deficiencies, eating habits and comorbidities. Foremost, nutritional patterns have gained high interest as possible promoters and modifiable risk factors for thyroid cancer in recent years. The aim of this narrative review is to focus on the relationship between thyroid cancer and nutritional factors, dietary habits and obesity. Low iodine intake has been associated to increased risk of thyroid cancer, favoring the development of more aggressive histotypes. Moreover, correction of iodine deficiency can shift thyroid cancer subtypes toward less aggressive forms, without affecting the overall risk for cancer. Actually, evidence regarding the association between selenium and vitamin D deficiency and thyroid cancer is very limited, despite their well-known anti-cancer potentials, and the clinical usefulness of their supplementation is still uncertain in this setting. Albeit the relationship between single foods and thyroid cancer is difficult to examine, fish and iodine-rich foods, vegetables, and fruits might exert protective effects on thyroid cancer risk. Conversely, no clear association has been found for other foods to date. Lastly, a clear association between obesity and the risk of thyroid cancer, with more aggressive behavior, seems to emerge from most studies, likely involving variations in thyroid function and chronic inflammation mediated by cytokines, insulin, leptin and adiponectins. Although no definite association between dietary factors and thyroid cancer has been firmly established so far, some nutritional patterns, together with excessive weight, seem to play a relevant role in thyroid cancer carcinogenesis as well as in its severity and aggressiveness. These effects may play an additive role to the well-established one exerted by environmental carcinogens, such as pollutants and radiation exposure.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.